Corlieve Therapeutics

EpilepsyGTx

This company develops precision gene therapies for patients with focal refractory epilepsy to provide seizure freedom.

Coave Therapeutics

The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.

Focalis

Focalis Bio develops gene therapies delivering engineered potassium channels to treat patients suffering from focal refractory epilepsy.

Lario Therapeutics

This company develops precision medicines for patients with severe neurological disorders, including epilepsy and Parkinson’s disease.

GenEp

The company develops therapies targeting ion channel mutations to treat rare genetic and treatment-resistant epilepsies for patients with unmet medical needs.

Neurona Therapeutics

This company develops off-the-shelf regenerative neural cell therapies for patients with drug-resistant epilepsy and other chronic disorders of the central nervous system.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

Arvelle Therapeutics

This biopharmaceutical company develops and commercialises antiepileptic medicines to treat patients suffering from central nervous system disorders.